Division of Renal Medicine, Department of Clinical Science, Technology and Intervention, Karolinska University Hospital, 14186 Stockholm, Sweden.
Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow G61 1QH, UK.
Toxins (Basel). 2019 Feb 1;11(2):82. doi: 10.3390/toxins11020082.
Together with bone-mineral disorders, premature vascular ageing is a common feature of the uremic phenotype. A detailed understanding of mechanisms involved remains unclear and warrants further research. Available treatment options for end stage renal disease are principally dialysis and organ transplantation, as other treatment alternatives have proven insufficient. Chronic kidney disease (CKD) has been proposed as a model of early vascular and bone ageing, with accumulating evidence supporting the contribution of cellular senescence and the senescence-associated secretory phenotype (SASP) to cardiovascular pathology in CKD. Correspondingly, novel therapies based around the use of senolytic compounds and nuclear factor-erythroid-2-related factor 2 (Nrf2) agonists, have been suggested as attractive novel treatment options. In this review, we detail the contribution of the uremic environment to these processes underpinning ageing and how these relate to vascular health.
与骨矿物质紊乱一样，过早的血管老化是尿毒症表型的一个共同特征。目前尚不清楚涉及的机制，需要进一步研究。终末期肾病的现有治疗选择主要是透析和器官移植，因为其他治疗方法已被证明无效。慢性肾脏病 (CKD) 已被提出作为早期血管和骨老化的模型，越来越多的证据支持细胞衰老和衰老相关分泌表型 (SASP) 对 CKD 心血管病理的贡献。相应地，基于使用衰老溶解化合物和核因子-红细胞 2 相关因子 2 (Nrf2) 激动剂的新型疗法已被提议作为有吸引力的新型治疗选择。在这篇综述中，我们详细描述了尿毒症环境对这些衰老相关过程的贡献，以及它们与血管健康的关系。
